ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling
This study revealed that ERBB3 was a key resistance factor driving limited efficacy to sequential regorafenib, but also an effective therapeutic target whose inhibition enhanced regorafenib sensitivity after sorafenib or lenvatinib resistance.
Authors
- Jing Lin (ORCID: https://orcid.org/0000-0002-8845-2719)
- Baorui Tao (ORCID: https://orcid.org/0000-0002-5103-402X)
- Jin Chen (ORCID: https://orcid.org/0000-0002-5557-2079)
- X. Wang (ORCID: https://orcid.org/0009-0005-5805-8875)
- Yan Geng
- Rongquan Sun
- Bo Zhang (ORCID: https://orcid.org/0000-0001-9780-9049)
- Yinchen Gu
- Chenhe Yi
Institutions
- Huashan Hospital (CN)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3350/cmh.2025.0972
- Primary Topic
- Hedgehog Signaling Pathway Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Program of Shanghai Academic Research Leader